## **REMARKS**

Claim 1 is amended herein. Support is found, for example, in the specification on page 37, line 7 and among the exemplary compounds on pages 38-46. Hence no new matter is presented.

Accordingly, upon entry of the Amendment, claims 1-20 will be all of the claims pending in the application.

Claim 1 is rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Boothe et al (GB 125453).

Applicants respectfully submit that independent claim 1 is amended herein to recite that m is 1 in the compounds of formula (I). Boothe et al does not disclose compounds within the scope of the present claims wherein m is 1. In the compounds disclosed by Boothe, m is 2. Therefore, the present invention is not anticipated by Boothe et al.

Accordingly, Applicants respectfully request withdrawal of the rejection.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

## AMENDMENT UNDER 37 C.F.R. §1.111 U.S. APPLN. NO. 10/813,622

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373 CUSTOMER NUMBER

Date: June 1, 2005